Our Products and Services
Oranoxis™ specializes in the development and manufacture of quantitative and qualitative immunoassays for drugs of abuse, food safety, environmental pollutants, and therapeutic drug monitoring. Our products meet high standards of accuracy, sensitivity, and precision due to our proprietary lateral flow platform technologies in addition to our strict quality management system. Please see our full product list, or click on the following product categories below for more specific details.
Oranoxis™ provides contract conjugation and nanoparticle technology services, and contract services for immunoassay development and manufacturing. We also provide consulting services for immunoassay R&D, quality control, and troubleshooting. Please see our full list of services for more information.
Please contact us for product and/or service inquiries, price quotations, and product distribution interests.
News and Events
Oranoxis™ is ready for AACC Conference in Philadelphia! Come see us at booth #4079 August 2-4
Oranoxis™ unveils new rapid test reader at DATIA 2016 Conference in Las Vegas, NV.
Oranoxis™ completes notification of all on-site drugs of abuse testing devices and receives new CE mark for Oral-AQ™, ToxWipe-Oral™, ToxWipe-Oral™ K2, and ToxStick K2™.
Oranoxis™ launches ToxWipe-Oral™ K2 and ToxStick K2™ for on-site drugs of abuse testing of K2/synthetic cannabinoids. ToxWipe-Oral™ K2 is one of the first rapid test devices on the market capable of detecting K2/synthetic cannabinoids in oral fluid, and ToxStick K2™ detects major K2/synthetic cannabinoids in urine with high sensitivity.
Oranoxis™ introduces a new product line, ToxWipe-Oral™, for on-site drugs of abuse testing. ToxWipe-Oral™ is designed to enhance convenience and ease of use for roadside and on-site preliminary testing, and allows for a more rapid sample collection by requiring a smaller volume of oral fluid.
Oranoxis™ successfully receives ISO 13485:2003 certification by NSF International.
National Institutes of Health (NIH) and National Cancer Institute (NCI) award Oranoxis™ with a grant for a contract project on the development of a rapid immunoassay for chemotherapeutic drug monitoring.
Oranoxis™ presents immunoassay R&D report at a conference held at Harvard Medical School.
Oranoxis™ launches On-site Oral-AQ, an oral fluid multi-drug test that has a removable sample retention cup for storing saliva samples for confirmation testing.